Accepted for Publication: October 1, 2020.
Published Online: October 20, 2020. doi:10.1001/jamainternmed.2020.6820
Corresponding author: Olivier Hermine, MD, PhD, Université de Paris, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Necker, INSERM, Imagine Institute, 149-161 rue de Sèvres, Paris 75743, France (ohermine@gmail.com).
Correction: This article was corrected on January 4, 2021, to fix errors in the supplemental group member list and to add the collaborative group in the end matter. These collaborators were previously not indexed in PubMed, but the error has been resolved. It was corrected again on May 3, 2021, to correct the spelling of 2 names in the nonauthor collaborators list in the Supplement.
Author Contributions: Drs Resche-Rigon and Porcher had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. The authors contributed equally to this study.
Concept and design: All authors.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: All authors.
Critical revision of the manuscript for important intellectual content: Hermine, Mariette, Tharaux, Resche-Rigon.
Statistical analysis: Porcher, Ravaud.
Obtained funding: Hermine, Mariette, Resche-Rigon, Ravaud.
Administrative, technical, or material support: Hermine, Mariette, Resche-Rigon, Ravaud.
Supervision: Hermine, Mariette, Tharaux, Ravaud.
Conflict of Interest Disclosures: Dr Tharaux has received honorarium fees for participation on advisory boards for Retrophin Inc not related to this work. No other disclosures are reported.
Data Sharing Statement: See Supplement 3.
Funding/Support: This trial was publicly funded (Ministry of Health, Programme Hospitalier de Recherche Clinique [PHRC COVID-19-20-0143, PHRC COVID-19-20-0029], Foundation for Medical Research (FRM), AP-HP Foundation and the Reacting program).
The CORIMUNO-19 Collaborative Group: The CORIMUNO-19 Collaborative Group members are listed in Supplement 4.
Role of the Funder/Sponsor: The funding agencies had no access to the trial data and had no role in the design, conduct or reporting of the trial. Roche donated TCZ in unrestricted grant, and had no role in the trial design or conduct; the collection, management, analysis, interpretation of the data; or in the preparation, review of the manuscript or the approval of the manuscript for submission.
Additional Contributions: We are grateful to all patients who participated in the CORIMUNO study, and their families. The authors also thank Pr Maxime Dougados, MD, in charge of the logistics, as well as the investigators who collaborated in this study (Supplement 4) and Universities of Paris, Paris-Saclay, Paris-Sorbonne, Paris-Nord Sorbonne, Paris-Est Créteil, Versailles-Saint Quentin, Strasbourg and Lille (Medical Students support), INSERM, and Reacting.
Additional Information: A coordination committee was responsible for the design, conduct, and reporting of the trial, and an independent data and safety monitoring board (DSMB) oversees all CORIMUNO trials (Supplement 4).
1.Wu
Z , McGoogan
JM . Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention.
JAMA. 2020;323(13):1239-1242. doi:
10.1001/jama.2020.2648
PubMedGoogle ScholarCrossref 5.Team TNCPERE: The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19).
China CDC Weekly. 2020;2(8):113-122. doi:10.46234/ccdcw2020.032 doi:
10.46234/ccdcw2020.032Google ScholarCrossref 8.Wu
J , Liu
J , Zhao
X ,
et al. Clinical characteristics of imported cases of coronavirus disease 2019 (COVID-19) in Jiangsu province: a multicenter descriptive study.
Clin Infect Dis. 2020;71(15):706-712. doi:
10.1093/cid/ciaa199
PubMedGoogle ScholarCrossref 9.Beigel
JH , Tomashek
KM , Dodd
LE ,
et al. Remdesivir for the treatment of Covid-19: preliminary report.
N Engl J Med. 2020;NEJMoa2007764. doi:
10.1056/NEJMoa2007764Google Scholar 10.Group
RC , Horby
P , Lim
WS ,
et al. Dexamethasone in hospitalized patients with Covid-19: preliminary report.
N Engl J Med. 2020;NEJMoa2021436.
Google Scholar 13.Zhu
J , Pang
J , Ji
P ,
et al. Elevated interleukin-6 is associated with severity of COVID-19: a meta-analysis.
J med virol. Published online May 29, 2020. doi:
10.1002/jmv.26085Google Scholar 19.Working
WHO ; WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research.
Lancet Infect Dis. 2020;20(8):e192-e197. doi:
10.1016/S1473-3099(20)30483-7
PubMedGoogle Scholar